2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4542 When MRD matters: Clinical interpretation and treatment decision-making after measurable residual disease testing in multiple myeloma

Ahmed Sawas, MD, Sophia Glickman2, Christoph Buhl, MD3, Daniel Pfeffer, PhD4, Gabriel Rios5
1 Flatiron Health, New York, New York, United States
2 Flatiron Health, New York, NY, United States
3 Flatiron Health GmbH, Berlin, Germany
4 Flatiron Health, New York, New York, United States
5 Flatiron Health, New York, New York, United States

Background: Measurable residual disease (MRD) testing is increasingly used in multiple myeloma (MM) as a marker of response and prognosis. Although real-world studies have described MRD uptake, modality trends, and MRD-outcome associations, less is known about how physicians interpret MRD results and whether they inform treatment decisions. We characterized MRD rationale, interpretation, treatment intent, and subsequent actions using a large language model (LLM)-enabled approach to extract clinical decision insights. 

Methods: This retrospective cohort study used the US-based, electronic health record-derived, deidentified Flatiron Health Research Database, comprising structured and unstructured data from academic and community oncology practices in the United States. Eligible patients had MM, structured activity in 2019 or later, and at least 1 MRD assessment after therapy initiation. 

Clinical decision insights were extracted from unstructured clinical notes with an LLM-enabled framework using clinician-informed variable definitions, prespecified and data-driven taxonomies, iterative error analysis, and independent validation. Domains included MRD testing reason, clinician interpretation, intent, post-MRD action, MRD-attributed action, MRD centrality, concordance, barriers/uncertainty, patient factors, and physician philosophy. 

Results: Among 22,580 patients in the dataset, 13,551 met eligibility criteria and 2442 (18%) had MRD testing. After applying MRD criteria, 5686 MRD tests were available, with a median of 2 tests per tested patient. Among MRD-tested patients, 1288 (53%) had at least 1 MRD-negative (MRD−) result and 1630 (67%) had at least 1 MRD-positive (MRD+) result; categories were not mutually exclusive. 

Testing modality was flow cytometry in 3299 tests (58%), next-generation sequencing/polymerase chain reaction in 1970 (35%), and unknown/not documented in 417 (7%). Molecular MRD testing rates increased from 14% in 2015-2019 to 35% in 2020-2024 and 52% in 2025 or later. MRD testing occurred in line 1 (43%), line 2 (25%), line 3 (13%), and line 4 or later (19%). Median time from line start to MRD result was 266 days; timing varied across line duration.

Reasons for MRD testing most commonly included response assessment, post-transplant assessment/surveillance, and routine monitoring. MRD− results were most often reassuring or consistent with deep/durable response, whereas MRD+ interpretations included concern for residual disease, uncertainty regarding clinical significance, or documentation as not clinically actionable. 

MRD centrality to treatment decision-making varied: mentioned but not actionable, 32%; primary driver, 25%; supportive information only, 21%; contributing factor, 21%; unclear, <1%. Clinician philosophy most frequently reflected MRD as supportive but not decisive.

Within 90 days after MRD testing, treatment episode analyses identified escalation, including consolidation in 2172 tests (38%), de-escalation in 118 (2%), and discontinuation in 342 (6%). Escalation was more frequent after MRD+ than MRD− (48% vs 26%), whereas discontinuation was more frequent after MRD− than MRD+ (8% vs 5%). 

Among MRD− episodes with continued therapy, reasons included standard maintenance approach, physician caution, high-risk disease features, residual biochemical abnormalities, patient preference, or no documented rationale. Among MRD+ episodes without escalation, reasons included clinical stability, low-level positivity not actionable, toxicity/frailty concerns, observation favored, or no documented rationale. 

Conclusions: In this large real-world MM cohort, MRD testing, especially molecular MRD, increased over time. MRD is being incorporated across MM treatment settings, but its role in decision-making is heterogeneous. Rather than uniformly triggering treatment modification, MRD often served as supportive or contextual information, with only a subset of episodes showing MRD as a primary driver. Post-MRD escalation was more common after MRD+, whereas discontinuation was more common after MRD−; distinguishing MRD-attributed decisions from temporal treatment changes is essential to avoid over interpreting causality. These findings extend real-world MRD analyses by characterizing how clinicians make MRD-informed decisions in clinical practice.

Ahmed Sawas, MD: Roche - Current equity holder in publicly-traded company; Pfizer - Honoraria; Eli Lilly - Honoraria; Flatiron Health, Inc. - Research Funding; Flatiron Health, Inc. - Current Employment